Stay updated with breaking news from Suraksha Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The intra-nasal vaccine for COVID received approval under restricted Use in emergency situations for ages 18 and above for primary two dose schedule, homologous booster doses, Union minister Dr Jitendra Singh said.
Central Drugs Standard Control Organisation (CDSCO) has granted approval for Bharat Biotech’s BBV154 vaccine to treat Covid-19.
Vaccine receives approval under restricted use in emergency situations for 18 and above
World's first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above.
NEW DELHI, December 1 : World’s first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above. This was informed here today by Union Minister of State (Independent Charge) Science & Technology; Minister of State (Independent Charge) Earth Sciences; MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr Jitendra Singh while chairing the meeting of the […]